Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02103257
Recruitment Status : Unknown
Verified April 2015 by Betta Pharmaceuticals Co., Ltd..
Recruitment status was:  Recruiting
First Posted : April 3, 2014
Last Update Posted : April 29, 2015
Sponsor:
Information provided by (Responsible Party):
Betta Pharmaceuticals Co., Ltd.

Brief Summary:
This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients with EGFR mutation.

Condition or disease Intervention/treatment Phase
EGFR Positive Non-small Cell Lung Cancer Adenocarcinoma Drug: Sequential Icotinib Plus Chemotherapy Drug: Icotinib Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 192 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study
Study Start Date : March 2014
Estimated Primary Completion Date : March 2016
Estimated Study Completion Date : September 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sequential icotinib plus chemotherapy
Sequential icotinib plus chemotherapy : pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
Drug: Sequential Icotinib Plus Chemotherapy
Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
Other Names:
  • ALIMTA
  • DDP
  • Comana, BPI-2009

Active Comparator: Icotinib
Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
Drug: Icotinib
Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
Other Names:
  • Comana
  • BPI-2009




Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 15 months ]
    A duration from randomization date to disease progression(as defined by RECIST) or death. If a participant are known to have progressed, the time to progression is defined as the time from the date of randomization to the date of progression. Otherwise, a participant will be censored at the last date they are known not to be progressed.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 24 months ]
    Overall Survival is assessed via calculation of the time to death due to any cause. If a participant is known to have died, the time to death is defined as the time from the date of randomization to the date of death. Otherwise, a participant will be censored at the last date they are known to be alive.

  2. Objective response rate [ Time Frame: 15 months ]
    Number of subjects with confirmed objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

  3. Adverse events [ Time Frame: 24 months ]
    The number of patients who suffered adverse events, which is graded by NCI CTCAE version 4.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT)
  • Patients must have previously untreated locally advanced or metastatic NSCLC
  • EGFR activating mutation (exon 19 deletion, L858R) is required
  • Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1

Exclusion Criteria:

  • Prior chemotherapy or treatment with gefitinib, erlotinib, or other drugs that target EGFR
  • Patients with wild-type EGFR
  • Any other investigational agents are not permitted
  • Any evidence of interstitial lung disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02103257


Contacts
Layout table for location contacts
Contact: Helong Zhang, MD 13709202616

Locations
Layout table for location information
China, Gansu
First Hospital of Lanzhou University Active, not recruiting
Lanzhou, Gansu, China, 730000
Lanzhou military region general hospital Active, not recruiting
Lanzhou, Gansu, China, 730050
China, Guangdong
General Hospital of Guangzhou Military Command Active, not recruiting
Guangzhou, Guangdong, China, 510010
Cancer Hospital of Sun Yat-sen Active, not recruiting
Guangzhou, Guangdong, China, 510060
First Affiliated Hospital of Guangzhou Medical College Active, not recruiting
Guangzhou, Guangdong, China, 510120
Jiangmen central hospital Active, not recruiting
Jiangmen, Guangdong, China, 529030
The university of Hong Kong-Shenzhen Hospital Active, not recruiting
Shenzhen, Guangdong, China, 518000
Shenzhen People's Hospital Active, not recruiting
Shenzhen, Guangdong, China, 518020
Medical Oncology,Shenzhen Second People's Hospital Active, not recruiting
Shenzhen, Guangdong, China, 518035
Thoracic Surgery,Shenzhen Second People's Hospital Active, not recruiting
Shenzhen, Guangdong, China, 518035
Peking University Shenzhen Hospital Active, not recruiting
Shenzhen, Guangdong, China, 518036
Guangdong Agribusiness Center Hospital Active, not recruiting
Zhanjiang, Guangdong, China, 524009
China, Guangxi
First Affiliated Hospital of Guangxi Medical University Active, not recruiting
Nanning, Guangxi, China, 530021
China, Hainan
Hainan Provincal Nong Ken Hospital Active, not recruiting
Haikou, Hainan, China, 570311
Hainan Provincial People's Hospital Active, not recruiting
Haikou, Hainan, China, 570311
China, Henan
First Affiliated Hospital of Zhengzhou University Active, not recruiting
Zhengzhou, Henan, China, 450052
China, Ningxia
Medical Oncology,General Hospital of Ningxia Medical University Active, not recruiting
Yinchuan, Ningxia, China, 750004
Radiation Oncology,General Hospital of Ningxia Medical University Active, not recruiting
Yinchuan, Ningxia, China, 750004
Respiratory medicine,General Hospital of Ningxia Medical University Active, not recruiting
Yinchuan, Ningxia, China, 750004
China, Shanxi
Baoji Central Hospital Active, not recruiting
Baoji, Shanxi, China, 721008
3201 Hospital, Hanzhong, Shanxi Active, not recruiting
Hanzhong, Shanxi, China, 723000
Shaanxi province people's hospital Active, not recruiting
Xi'an, Shanxi, China, 710000
Second Affiliated Hospital of Xi'an Jiaotong University Active, not recruiting
Xi'an, Shanxi, China, 710004
Xi'an Chang'an Hospital Active, not recruiting
Xi'an, Shanxi, China, 710018
Tangdu Hospital,Fourth Military Medical University Recruiting
Xi'an, Shanxi, China, 710038
Contact: Helong Zhang, MD    13709202616      
Principal Investigator: Helong Zhang, MD         
First Affiliated Hospital of Xi'an Jiaotong University Active, not recruiting
Xi'an, Shanxi, China, 710061
Shanxi Cancer Hospital Active, not recruiting
Xi'an, Shanxi, China, 710061
China, Xinjiang
Urumqi General Hospital of Lanzhou Military Region General Hospital Active, not recruiting
Urumqi, Xinjiang, China, 830000
Xinjiang medical university affiliated tumor hospital Active, not recruiting
Urumqi, Xinjiang, China, 830000
First Affiliated Hospital of Xinjiang Medical University Active, not recruiting
Urumqi, Xinjiang, China, 830054
Autonome Region Xinjiang Uygur Chinese medicine hospital Active, not recruiting
Urumqi, Xinjiang, China, 830099
Sponsors and Collaborators
Betta Pharmaceuticals Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Helong Zhang, MD Tang-Du Hospital

Layout table for additonal information
Responsible Party: Betta Pharmaceuticals Co., Ltd.
ClinicalTrials.gov Identifier: NCT02103257     History of Changes
Other Study ID Numbers: BD-IC-IV62
First Posted: April 3, 2014    Key Record Dates
Last Update Posted: April 29, 2015
Last Verified: April 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Adenocarcinoma of Lung
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type